

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: **A61K 45/06**

(21) International Application Number: **PCT/EP01/06976**

(22) International Filing Date: **20 June 2001 (20.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). **HABEREY, Mar-
tin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIER-
AUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/97850 A2

(54) Title: **COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE
RECEPTOR FUNCTION AND THEIR USE (II)**

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonnier et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-peri endothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

- VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).
- 10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
- 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
- 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
- 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).
- Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
- 30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine


kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhUMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I



I,

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

9

b) together form a bridge of general partial formula II,




5

wherein the binding is via the two terminal C- atoms, and
has the meaning of 0 to 4; or

m

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the
meaning of nitrogen, and each others have the meaning of
CH, and the bining is via the atoms T_1 and T_4 ;

G

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or
 $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkeny-
lene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$,
 $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$,
 $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

20

A, B, D, E and T

independently from each other have the meaning of N or CH ,
with the provisio that not more than three of these
Substituents have the meaning of N,

25

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated
- 10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
- 15 more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese, respectively, which results in a prevention of tumor growth and tumor spread, are for example

anthranil acid derivatives of general formula IV

30




in which

A has the meaning of group $=NR^2$,

5 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q$, branched or unbranched C_{1-6} -Alkyl or is the group


10



15

or A, Z and R^1 together form the group

20



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

5

X

Y

p

R¹

15

R²

20

R³

25

R⁴, R⁵, R⁶ and R⁷

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,

has the meaning of group -(CH₂)_p,

has the meaning of integer 1-4,


has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or

C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group




5 R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V




V,


15

in which
R¹


has the meaning of group

20






in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,



in which R^8 is $-\text{CH}_3$, fluoro, chloro or $-\text{CF}_3$


in which R^4 is fluoro, chloro, bromo, $-\text{CF}_3$, $-\text{N}=\text{C}$, $-\text{CH}_3$, $-\text{OCF}_3$ or $-\text{CH}_2\text{OH}$

in which R^6 is $-\text{CH}_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

25

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least
10 one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.
- Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

- The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites
5 formation in patients. It is also possible to suppress VEGF oedemas.
For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
- 30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, maligneous nephrosclerosis, thrombic microangiopatic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the
- 15 tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
 20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of

5 the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of

10 intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

15

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

10

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

30

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 10 2. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I
which modulates the biological function of one or several of the VEGF/VEGF
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems
and comprising one or several agents as compound II which are targeted to
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a


14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

25

15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I

30

41



in which

5

 r

has the meaning of 0 to 2,

 n


has the meaning of 0 to 2;

 R_3 und R_4

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,




15

wherein the binding is via the two terminal C- atoms,
and m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

20 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, lower-alkyl-sulfonyl, or alkylphenylsulfonyl,


25 phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

30

or double bonds; or an N-oxide of said compound,
wherein one or more N-atoms carry an oxygen atom,
or a salt thereof,

and/or a compound of general formula IV

5



in which

A

has the meaning of group $=NR^2$,

10


W

has the meaning of oxygen, sulfur, two hydrogen atoms
or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$,
 $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the
group


15



or A, Z and R^1 together form the group

20

44




5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and or R _d or R _e together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
15	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
25	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R^4, R^5, R^6 and R^7

5

substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl or C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group




R^8, R^9 and R^{10}

10

independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts,

and/ or a compound of general formula V

15




V,

20


in which

R^1 has the meaning of group




in which R^5 is chloro, bromo or the group $-OCH_3$,

5



in which R^7 is $-CH_3$ or chloro,



in which R^8 is $-\text{CH}_3$, fluoro, chloro or $-\text{CF}_3$


in which R^4 is fluoro, chloro, bromo, $-\text{CF}_3$, $-\text{N}=\text{C}$, $-\text{CH}_3$, $-\text{OCF}_3$ or $-\text{CH}_2\text{OH}$

in which R^6 is $-\text{CH}_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
20. Pharmaceutical compositions according to claims 1-17 which comprise as
10 compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.
- 25




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10 <120> Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

35

40

45

50

55

60

```
ttttacagtt ttccttttct tcagagttaa ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaaca gccaaaaaac cataatgggtg ccacagggat ggagcagggg agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaaccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctggt gtcactgtca aaaaggcact 540
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgtgaga 600
tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 660
tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccaaaacgca acctaaccaa agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgtaa gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcatagcg tcatttaatg ttaaagccca tcaggggcct ctccctcccg 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcgg tctggctgct tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgaccctc caacaagcat cgcagggcac 1500
tgtctcggg ggtacagacc gtggtccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgctgtag gccgtgctgt ctggggctcg aggtcttttc tgctgggtgct 1620
cttgacggg cggttagttc tgctgcagag acaaagcatc tccccctccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
gagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct
```

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagacc ctggggcctg tgctaccag 60
 acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tcctgtggcc cattagggaa gtgggtgacct cgggagctat ttgcctgttg 180
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
 tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
 agttatagtt catcacacag tgatttccat ttataaaggc agaaagtcct tgttttctct 420
 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaag tgtaggcct 540
 cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
 tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
 25 ttgttaagct tcgtggccag agtactgatt ctcttcacac gactatatgt cggaaaccaa 240
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tcttgcgcat tgcaggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataaca 420
 30 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480
 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 35 <213> Human

<400> 4

cccacaacac agggggcctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
 40 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
 ccacggggag gtagaagaag acctggctcg tgtaagggtc tgagaagggt ccctgggtcg 180
 ggggtgctgc ttggccttgc cgtgccctca tccccggct gaggcagcga cacagcaggt 240
 gcaccaactc cagcaggtta agcaccagg agatgagtcc aaccaccaac atgaagatga 300
 45 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcaggtg 360
 ctgcgtggca cacaacacag ggctccatgg tccagccgta caggcgccac tggccataga 420
 ggaagcctgc ctctagcaca ctcttgaga gcacactggc gacataggtg cccatcagt 480
 ctccgcggat gcgcaggcga ccatcttctg ccaccgagat cttggccatc tgacgtcta 540
 cgcccgccag cgcccgctcc acctgtgggt ccttggccgg cagtggccgc agctccccct 600
 ccttctgccc cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660
 50 ggggtgggtg gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720
 aggcctggtc atagcagaag ttggtgcagc ctgggtgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
 agagcaccgt cagccagatc ttaccacca cggctcagtg ctccctggacc tggctccagca 900
 acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
 55 gcacgtcagt gtgtcagcat ggcaccttc tcgttcgccc agcaacaagc ctgcaggag 1020
 gtctgccacg ccggttctac cgcctgcctg ccgggcggcc cagggtggag tggggacgat 1080
 ggcggagtg acgcccgcg

<210> 5
 60 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65

gaggataggg agcctggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

5 aaaaagtgct ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttggattt 120
 agtgggggagc ataatagcaa acacccctt gggttcgcaca tgtacaggaa tgggacccag 180
 ttgggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaaagtg gggccagggc 240
 ccagacccaa gaggagaggg tggtccgcag acacccggg atgtcagcat cccccgacct 300
 10 gcttcttgcc ggcacctccc ggggtctgtg ttgagtcagc aggcattggg tgagagcctg 360
 gtatatgtctg ggaacagggt gcaggggcca agcgttcttc cttcagcctt gacttgggccc 420
 atgcaccccc tctcccccaa acacaaacaa gcaacttctcc agtatgggtc caggacaggt 480
 gtcccttcag tctcttggtt atgacctcaa gtccacttg ggcctgcag cccagcctgt 540
 gttgtaacct ctgcgtcttc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
 15 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
 aatgtgcttc cctccctggg gtctcacacg ctccacagag aatgccacag gggccgtgca 720
 ctgggcagggc ttctctgtag aacccaggg gcttcggccc agaccacagc gtcttgccct 780
 gagcctagag cagggagtc cgaactctg cattcacaga ccacctccac aattgttata 840
 accaaaggcc tctgttctg ttatttcaact taaatcaaca tgctattttg ttttcaactca 900
 20 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgttca cgtgctagtt 960
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

 <210> 6
 <211> 2313
 <212> DNA
 <213> Human

 <400> 6

 25 ccagagcagg cctggtggtg agcagggagc gtgcaccgga cggcgggagc gagcaaatgg 60
 gtctggccat ggagcacgga ggttcctacg ctcgggcggg gggcagctct cggggctgct 120
 ggtattacct gcgctaactt tctctcttcg tctccctcat ccaattcctc atcatcctgg 180
 ggctcgtgct cttcatgggt tatggcaacg tgcacgtgag cacagagtc aacctgcagg 240
 30 ccaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300
 ccaacttgac caaggagctc aacttcacca cccgcgccaa ggatgccatc atgcagatgt 360
 ggctgaatgc tcgccgcgac ctggaccgca tcaatgccag cttccgccag tgccagggtg 420
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcagctga 540
 atcagaaggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600
 35 ataaggaaag cgtgctgctg aacaaacgcg tggcggagga acagctggtt gaatgcgtga 660
 aaaccgggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaaggtgca 720
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840
 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
 40 ggtggaggag ctggcccggg gcctccgggc ggatatcgaa cgctgggccc gcgagaactc 960
 agacctccaa cgccagaagc tggaaagccc gcagggcctg cgggccaagt agggagcga 1020
 acagaaggtg gagaaggagg ctcaggcccg ggaggccaag ctccaagctg aatgtcccgc 1080
 gcagaccagc cttagcgtgg aggagaaggc ggtgctgcgg aaggaacgag acaacctggc 1140
 caaggagctg gaagagaaga agaggaggc ggagcagctc aggatggagc tggccatcag 1200
 45 aaactcagcc ctggacacct gcatcaagac caagtcgag ccgatgatgc cagtgtcaag 1260
 gcccatgggc cctgtcccca acccccagcc catcgacca gctagcctgg aggagttcaa 1320
 gaggaagatc ctggagtcct agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380
 ctgaggaggc tccaggcctg aggaccaagg gatggccgga ctcgccggtt tgcggaggat 1440
 gcagggatat gctcacagcg cccgacacaa ccccctccc cgcccccaa ccaccaggg 1500
 50 ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcaccgcgc 1560
 cctcacgac cctcaccag agcacacggc cgcgagatg acgtcacgca agcaacggcg 1620
 ctgacgtcac atatcaccgt ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680
 tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740
 acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800
 55 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagt 1860
 acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920
 ccttttcaca cacactttct acccaattct cacctagtgt cacgttcccc cgaccctggc 1980
 acacgggcca aggtacccac aggatcccat cccctcccgc acagccctgg gccccagcac 2040
 ctcccctcct ccagcttcct ggcctcccag ccacttcctc acccccagtg cctggaccgc 2100
 60 gaggtgagaa caggaagcca ttcacctccg ctccttgagc gtgagtgtt ccaggacccc 2160
 ctcggggccc tgagccgggg gtgaggggtc cctgtgtcgg ggaggggagc cactccttct 2220
 cccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280
 agtaaatcct taaaaaaaaa aaaaaaaaaa aaa

 65 <210> 7
 <211> 389

<212> DNA
<213> Human

<400> 7

5 gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tatttctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgat atatttgtct gaatttgttc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8
15 <211> 157
<212> DNA
<213> Human

<400> 8

20 tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggtttttag 60
gaagcaggaa gcaagccac tcaaacgtga aatttgcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25 <210> 9
<211> 561
<212> DNA
<213> Human

30 <400> 9

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
tgaactgaac tattctgtta catatggttg acaaatctgt gtgttatttc ttttctacct 180
35 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccatatt aaaactgtca attattgcct aatgtttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgac 480
40 ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgcccacat ttctaggaaa a

<210> 10
45 <211> 1508
<212> DNA
<213> Human

<400> 10

50 cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60
tcgcagggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtagcag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaactc 240
gagctcaagc caggtagcgt taagccactg agcaaggaa atttgggcct gcacgcctac 300
55 aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctaccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaacgtgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgtcgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
gggtgcatgt ccctcttttt gccttggtta tgggtgtacc ttccagccaa ggggtgcctt 600
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaatg tcccactgtc cccctagga actttgaaaa acccaacatg 720
catcattaat caggaaatatt acagtaatga ggattttttt tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgg gatagctttt 840
gctgtttgcg gtgaaatgct ttttgcccat gtgccgtttt aactgatatg cttgttagaa 900
65 ctacagctaat ggagctcaaa gtatgagata cagaacttgg tgacctatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaaag tttttgtttg tgaatagtac ttgcaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatattttt 1080
 gtatatataa taatatttgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaatat tatactaata tgttgtagat tcggaagaat gtgaatcaat cagtattgtt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 10 ttcattgtata ttgtacagtt acagtataat tcaaccttta ttttctaatt ttttcaacat 1320
 attgtttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattttta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa
 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11
 20 gggcaggtga tcagggcaca catttcccg ccatgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtagagaca agtgcccgac 120
 aggatgggtg gccacagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360
 acctcgcccg cgaccacgct gggtagccga
 25 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12
 35 tttttttttt ttggattgca aaaatttatt aaaattggag aactgtttt aatcttcttg 60
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcaaaa tacaattgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatcatat tatatttcat ttggcagaat 360
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 40 taggataaca ggtctgcctg tttgaagatg aaaaaataa cccatttaaa atttgcccta 480
 ctcaatttcc ttctcagtca cattttaact tttaaacagc taatcactcc catctacaga 540
 ttaagggtga tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagttaaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 cacacagtg agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 45 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccacat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taagggtgta tccagagcca 900
 cactgcatct gcacccagca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960
 ataagagttc tttttagtgac g
 50 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 55 <400> 13
 60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggcccgagag catgtgactg ctggggacctc tgggataggc aacactgccc 120
 tctctcccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctacca gcacactctc tttactgcca cctgcaatta tgtgtgaa atgactgggt 240
 gtgggtcatca cgattcagag aaatcaagat ctatgacat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaactctc 360
 acttcagcat atttagttgt cattaaaatt aagctgatat t
 65 <210> 14

<211> 1002
<212> DNA
<213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
10 tttgaaaatg ttaaatataa gtcctattct ctttgtccag ctgggttttag cttagaggtag 180
ccaattactt ctcttaagggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaaata tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcat ttttactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
15 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaac aatgggtgcca tatgtcccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaagtgga gtagtaacca agcttttctg cccaggaagt acaaacatc 660
actacgaaca tgagagtaca agaggaaaact ttcataatgc attttttcat tcatacttc 720
attcaataaa cattagccaa gctaagtgtc caagccactg tgccagggtat taacaatata 780
20 acaacaataa aagacacagt ccttcctctc aagggtgttca gtctagtagg gaagatgatt 840
attcattaaa atttttgggtg catcagaatc atgaggagct tgtcaaaaat gtaaatcct 900
gcctatgttc tcagatatcc tggttaggtc aggagtgagg acccaaaatc aattccttta 960
acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

25 <210> 15
<211> 280
<212> DNA
<213> Human

30 <400> 15

cgaggtgggc caccctgttc tgggtctgaga tttttaaatg aggattacat tatectatct 60
ataatattcc tattctaate tattgtattc ttacaattaa atgtatcaaa taattcctta 120
aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
35 aactgtatta tgactctcaa tttttaaaca ttttaaaaaa tgtagtggtt tgtaagcac 240
caatcttaac tatttcacct gcccggtcgg cgcctcgagg

40 <210> 16
<211> 2041
<212> DNA
<213> Human

<400> 16

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagaacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
50 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaaaa gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
caggtacata ttttctctg aacatttttg gtcaagcatg tctaaccata aaagcaaag 540
gaattttaag aggtagattt ttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaga 660
tagatatattg ttatagtctg acatttttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaaatac agtctgcca actgtattaa atcctcctcc 780
acccctcca ccagttgggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gaggggcccg gctcgagcat tcaactcttg 900
60 ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataaag tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
ttgacatttc cttattttcc aaatcctggt caaaaactgc actgggacta tctctcccta 1200
65 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctggtggtag atctgatag 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

5 taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380
 catcagtgccc tgaaggcttt aatttttttag caaggttctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500
 ccaaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560
 10 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620
 gttttctcag cattttgcag agaggcacag ttttcacaat aatattgggt atcaccagta 1680
 agaattctctg gagcccaaaa aataatttag taagtcagtt actgaagggt tggtttcacc 1740
 tcccggtttc tgaggtagat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800
 15 agtggtttca gaacagtaaa actcattagg aggactgcct atggtttttt cattcacaag 1860
 20 tgagtcacag atgaaggcag ctgttggttg attataaact actggctctt ctgaaggacc 1920
 gggtagacag gcttgcatga gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaagat ctgtaaaggc 2040
 t

15 <210> 17
 <211> 235
 <212> DNA
 <213> Human

20 <400> 17

25 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagaccctc 60
 acctctacaa ataaaaaatt aaaaaattag ccaggtgtgg cagcgaacaa ctgtagtctc 120
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aagggtacag 180
 30 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta

<210> 18
 <211> 2732
 <212> DNA
 30 <213> Human

<400> 18

35 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120
 aaatattatc ttcttggtga tcacattgtg caaaatgggt aagcattcaa acactttgaa 180
 accagattct agcaggttgg aaaaacttaa gtcttgggtg cttggcgctt tcgctcttct 240
 gtgtcttctt ggccctcacct ggtcctttgg gttgcttttt attaatgagg agactattgt 300
 gatggcatat ctcttacta tatttaatgc tttccaggga gtgttcattt tcatctttca 360
 40 ctgtgctctc caaaagaaaag tacgaaaaga atatggcaag tgcttcagac actcactatg 420
 ctgtggaggc ctcccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480
 cagtgtctgc tattcctctg gcacacagag tctgtataaga agaattgtgga atgatactgt 540
 gagaaaacaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600
 tcaaggtggc ataaatctta atatatatt acaggactga catcacatgg tctgagagcc 660
 45 catcttcaag atttatatca ttttagaggac attcactgaa caatgccagg gatacaagtg 720
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840
 agaaaatgat catttcagaa ttagtgacaa acaacttacg gggcagcagc aagactcaca 900
 acctcgagct cagctacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960
 50 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggtg gagctccatc 1020
 acaaagaact cgaggcacca cttattcctc agcggactca ctcccttctg tacciaacccc 1080
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacct acagtcccc aacagagact ctctttatc aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agccctgaca tggaaagaaga cctctctccc tccaggagga 1260
 55 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc aggggcaata gtgatgggta tataatcccc attaacaag 1380
 aagggtgtat tccagaagga gatgttagag aaggacaaa gcagctgggtt acaagtcttt 1440
 aatcatacag ctaaggaatt ccaagggcca catgcgagta ttaataaata aagacacat 1500
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560
 60 tgggtgtaaaa aagatgactg aaccttgacg ttctgtgaat ttttataaaa catacaaaaa 1620
 ctttgatatat acacagagta tactaaagtg aattatttgt tacaaagaaa agagatgcca 1680
 gccagggtatt ttaagattct gctgctgttt agagaaattg tgaaacaagc aaaacaaaac 1740
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800
 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860
 65 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920
 tttgcagttc actgcaaact ttttacatta aggcaagat tgaaaacatg cttaaccact 1980

5 agcaatcaag ccacaggcct tatttcatat gtttctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatattttg ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160
 aaaagctctt ggttgacacat gttatgaaat gtttttctt acactttgtc atggttaagt 2220
 ctactcattt tcacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280
 tattacttac atttaaatctt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400
 tgtcacccct gtttattctt gaacagaggg caaagagggc actgggcaact tctcacaaac 2460
 10 tttctagtga acaaaaggtg cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520
 actcttccat attccttctg cctatatatta gtaattaatt ttttttatga taaagtctta 2580
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640
 ttaataatga gcccatcact aatatccagt gtaaagttaa acacgggttg acagtaaata 2700
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

15 <210> 19
 <211> 276
 <212> DNA
 <213> Human

20 <400> 19

25 ctccctaaat gattttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120
 tattccctat atagcaaac aaacacagga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gccgcgacca cgctgg

30 <210> 20
 <211> 2361
 <212> DNA
 <213> Human

<400> 20

35 attgtaccag ccttgatgaa cgtgggccct gcttcgcttt tgagggccat aagetcattg 60
 cccactgggt tagaggctac cttatcattg tctcccgta ccggaagggt tctcccaagt 120
 cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttctg 240
 40 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300
 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360
 ttgccaagag ccagcatctg gacagtgtat ggtgggcccc gattttcatg cagtatggag 420
 accatctcta cagcaagggt aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480
 gaaagtggga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccaccc 600
 45 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatacaaga 660
 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggt ctcggcagg 720
 ctggtctacta ctcccatgcc ctgtatctgg cggagaacca tgcacatcat gagtggatcc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggaagc 840
 tgctttttga gcaggcagag agcaacatga agcgctacgg caagatcctc atgcaccaca 900
 50 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgcag cgatagggag gccccaggct gcagggcccc ctctgaggag ttcattccca 1020
 tctttgccaa taaccgcgga gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggccc 1140
 acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200
 55 gtggtcgctt ctgagcagtc tttgacaagg ccctggctct gtgccagatg cagcacttcc 1260
 aggatgggtg cctttacctt tatgagcagg ggaagctggt ccagcagatc atgcactacc 1320
 acatgcagca cagcagtagc cggcaggtca tcagcgtgtg tgagcgccat ggggagcagg 1380
 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcc aactcttctag 1500
 60 tgggtgcagac cctggcccac aactccacag ccacactctc cgtcatcagg gactacctgg 1560
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcggt 1620
 accgagagga gaccacccgt atccgcccagg agatccaaga gctcaaggcc agtccctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740
 65 tcctgtgtgg cactccttc caccacact gctttgagag ttactcgga agtgatgctg 1800
 actgccccac ctgcctcctt gaaaaccgga aggtcatgga tatgatccgg gcccggaac 1860
 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

ctgtgattgc tgactacttt ggcagagggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggtctgggt gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 agaacagaca caatgggacc tgggcgggcy ttacacagaa ggctggctga catgccagg 2160
 5 gctccactct catctaattgt cacagccctc acaagactaa agcgggaactt tttcttttcc 2220
 ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaac tcctgaagt 2340
 ttgaaaaaaa aagctggtt c

10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

15 <400> 21

aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

20 <210> 22
 <211> 905
 <212> DNA
 <213> Human

25 <400> 22

tttttttttt ttctttaacc gtgtggtctt ttttccagt cccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaacg gaatgccaa gtcgaagcca ggctcaagaa 120
 30 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttccctaaagg 180
 caaagggtact tttgatacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300
 tagggctcatt aataactatg aatatatctt ttagaagggt accatttttc actttaagg 360
 gaatcaattt tgaatatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 35 gggagctgga agagccttgg aagtttctat tacaatatga gcaccatata cttcatgcca 480
 aatctcaaca aaagctcttt ttaactccat ctgtccagt tttacaaata aactcgcaag 540
 gtctgaccag ttcttggtta caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaaggc taccaggagc ctaatgcctc ttccaacat tgggggaacc agtagaaaaa 660
 ggcagggtc cctaattgtcc attattacat ttccattccg aatgccagat gttaaaagt 720
 40 cctgaagatg gtaaccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780
 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaaagtga tgttttttcg 840
 ccatggattg cagtccctct ctccagacca gctgcttatt tcctcagggg cccagggaat 900
 gttga

45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

50 <400> 23

ggtctcttct ttcctttttt tttttccaaa agtgttcttt ttttctagt aacatatatt 60
 gtataaatac tctattttat atgcaactcc acaaaagcga tataatttaa aagttttttt 120
 cattagaat aaatgtataa aaataaatat gttattatag gcattttatta ctaactatag 180
 55 tccttcttgg aaggaaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300
 accaggatac gactgttgga ccagctgtg gaggatggacc tgctaccct cagcagcctc 360
 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420
 tcatttttgt tccggcggtt catcctcctt gtgtgattgt actgattttc atgagacaca 480
 60 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaaag 540
 tggaggtact aagctcattg tgtctcctct agcttttacc agcatctaag gcttactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagtgtt ttttctctca 660
 aaatgaatta cacaataaaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720
 gttattttcac gttgctgagc ctttctctca tgtgaacaa tctgaagttt taattctcgg 780
 65 tagaaataat gtataaacat tctctgaac catagcagcc ataaacagt ctgggtcaaa 840
 atcctatttg tactcctttc tccccccatt gttagtggag taaagtaaaa cagggtcttag 900

5 taaaaatctca cttttctect acttttccatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatatgt ctaacttttt ttgacaattg ctttggtttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccg ggctttatta 1080
 tgctatatca ctgctcagag gttaataatc ctactaact atcctatcaa atttgcaact 1140
 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc caccttactg 1200
 atacacctca ctgggtactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttctctactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgttttagg tttctttaaa ggatcacagc 1380
 tctcatgaga taacaccctt ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 10 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctggtg ctggctggct tcaacttctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgaccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taatttttagg tcgaagggca ttgcccacag 1740
 15 taagaacctg gatggtcaag ggctctttga gagggtctaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacctttgta cataatgtct tgctctaagg 1860
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gttcctggat cccctctggt tccgctggtt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatata caggttttgc actagtaact gatcctgata 2040
 20 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttgg 2100
 agtctatgat gcgatcacia ccagctttta caca

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatattttgg 60
 ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gttaaaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacagggt gaacaaacgt 240
 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300
 35 gaaaaaggca agacaaatgg cctctgttac tgaatacttc ggcaaaactta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttgtagagc ttgcttagaa tggattacat 420
 ggtagtgtat cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480
 aatcctttat gtctttttat tgtaagcata tctgaattta ctttataaag atggttttag 540
 aaagctttgt ctaaaaattt ggcctaggaa tggttaacttc attttcagtt gccaaagggt 600
 40 agaaaaataa tatgtgtgtt gttatgttta tgtaaacata ttattaggtta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaaac tcaggttacc cttgaaggat atgctggcag 780
 ccactctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840
 tctggaatgc attagttatg ccttgtacca ttcccagaat ttcaggggca tctgtgggtt 900
 45 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 50 cggtgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtag tgcaatcaca 1320
 atgacagatg gtgtttatgg gctatttggg taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcatcttat ggaaactctt gatgcagtgt cttttgtatg gaataaattt 1440
 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 55 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatatatt 1560
 tacttgaaaa tattttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa

<210> 25

<211> 1420

60 <212> DNA

<213> Human

<400> 25

65 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

ttcattgaaa tccttgctac ttctcttcct cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttggaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240
 agtgggaaaa cttaagagt ttccacatat tagttttcat ttttgagtc aagagactgc 300
 5 tccttgactt gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360
 tattttataa ggccataaaa tactgggttaa actctgttaa aagtgggcct tctatcttgg 420
 atggtttcac tgccatcagc catgctgata tattagaaat ggcaccccta tctacttact 480
 ttaatgctta aaattatata taaaatgctt tatttagaaa acctacatga tacagtgggtg 540
 tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600
 10 aggggtggaga aagaggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
 atccttttgc tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
 tttgctctgt tttgcctgaa gttttagtag ttgttttcta ggtggacctc tgaaaaccaa 840
 accagtacct ggggaggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgct 900
 15 tgtatttttc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960
 gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttgggt aggttactgt 1140
 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa atttgtttt 1200
 20 tatagaaatt ttttatactg attggttcat agatggtcag tttgtacac agactgaaca 1260
 atacagcact ttgccaaaaa tgagtgtagc attgttttaa cattgtgtgt taacacctgt 1320
 tctttgtaat tgggttgtgg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
 agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa

25 <210> 26
 <211> 689
 <212> DNA
 <213> Human

30 <400> 26

aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60
 caaacaatta tagcacatcc ttctttttac tctgtctcac ctccttttagg tgagtacttc 120
 cttaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcctta 180
 35 ggtaatcagc ctagtttaca ctgtttccag ggagtagttg aattactata aaccattagc 240
 cacttgtctc tgcaccattt atcacaccag gacagggtct ctcaacctgg gcgctactgt 300
 catttggggc caggtgattc ttccttgcaa gggtgtcct gtacctgcc ggcggccgc 360
 tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agctctggct gccctcagga 420
 attccaatg accgaaggaa caaagcttca gggctctggg tgggtgtctc cactattcag 480
 40 gaggtggctg gaggtaacgc agcttcatc cgtccagtcc tttccagtat ttaaagttgt 540
 tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660
 cacaccaga gcctgaagtt tgtccttcg

45 <210> 27
 <211> 471
 <212> DNA
 <213> Human

50 <400> 27

tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60
 ccctctcgct cattgggtgg accctgcttt gctgtcctg ccaggacgag gcaccctaca 120
 agccctaacc caggcccccgc ccagggccac cagcaccact gcaaacaccg cacctgccta 180
 55 ccagccacca gctgcctaca aagacaatcg ggcccccctca gtgacctcgg ccaccacagc 240
 gggtagcaggc tgaacgacta cgtgtgagtc cccacagcct gcttctccc tgggtgctg 300
 tgggtgtggt cccggcgga ctgtcaatgg aggcaggggt tccagcacia agtttacttc 360
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
 60 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

<210> 28
 <211> 929
 <212> DNA
 <213> Human

65 <400> 28

5 ggtgaactca gtgcattggg ccaatggttc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctggtggg ctttcccctc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc ctttggatgc accctgtcgc accaagaaca tcgcccggga 180
 gattccaccc cagccctggt acaagtctac tgtcatccac atgactgttg gaggttctct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtaacct ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgactca cctacttcca gttgtctggg gaggattacc gctgggtggg 420
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcate ttctctact cagttttcta 480
 ttatgcccg cgctccaaca tgtctggggc agtacagaca gtagagttct tcggctactc 540
 cttactcact ggttatgtct tcttctcat gctgggcacc atctcctttt tttcttccct 600
 aaagtctatc cggatatatct atgttaacct caagatggac tgagttctgt atggcagaac 660
 tattgctgtt ctctcccctt ctctcatgcc tgttgaactc tcctaccagc ttctcttctg 720
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780
 15 ccagagaggg cctggaaatt ataaatctct atcacataag gattatataat ttgaactttt 840
 taagtgcct ttagttttg tcttgatttt tctttttaca attacaaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29
 20 <211> 1775
 <212> DNA
 <213> Human

<400> 29

25 gaacgtgatg ggaacttttg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gtttccaaa aaattactca 120
 ttgacaattc aaattgcaact tggctggcgg cagcccgggc ggccttcagt ccgtgtgggg 180
 cgcccgcgtg gccttctcct cgtaggactc cccaaactcg ttactctgct gtttatccac 240
 30 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgat gaaggcgaag acgtcatcaa tgaagggtgt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca actttagtt 420
 cacaagagc tggggcagca tgaagaggaa accaaaggca tagaccccgt tgacgaagct 480
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 35 cccgacacag agagggtaca gcaggatatga caagtacttc atggcctgag tatcgtactc 600
 ctccggtttt ctctcagatt cgtgtgaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcattctca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgctc agcaggaaca gaaagatgac 780
 cacgggtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgctcttctt 840
 40 cttcttccag aaactgatgt cttttttaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccaggaaagta taagtggta tctacaaaaa ttcctttcac 960
 ctcacagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gccccagtga gacctgtcg taggacacgg tgaggggcag 1080
 ctccggtggtg gagcggttta tgaccatcag gtccttcacg cggttgctga gctggtcgat 1140
 45 gaacaggatg ggcaggtaat gcacggtttt ccccagctgg atcatcttca tgtaaccgat 1200
 cacatcggca ggcaggagg acccgtcaaa gacaaagtgt tccgcacatca cgttcagcgc 1260
 cagccgcggg cgccagtggg acactggctc atccagggca ctcgctggct tcttctccgc 1320
 ctcgatctgc tgtgtatcag actccccggt gagcagggtg atttcttctg gcttggggac 1380
 catgtagggt gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440
 50 cccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgtttctcg ttttcttttg 1500
 tacagaataa ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggtcg atgttgttct cagcaccagc gtgggacctc gtcgtggtgt acacgctcag 1620
 ctgcagcttg agcgcccgcg ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 gcgggtgtag acgatgccgt acatgacca gcagggtgac accacgtaga ccacgaacac 1740
 55 gccaccacc aagctggtga aggagctgcg gcccc

<210> 30
 <211> 1546
 <212> DNA
 60 <213> Human

<400> 30

aaaataagta ggaatgggca gtgggtattc acattcacta cacttttcc atttgctaat 60
 65 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120

5 acaccatcta cgggcacccat ggaactgctt caagtgacca ttctttttct tctgcccagt 180
 atttgcagca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttgttact 240
 acaacaaaac catctataac aacaccaaac acagaatcat tacagaaaaa tgttgtcaca 300
 ccaacaactg gaacaactcc taaaggaaca atcaccaatg aattacttaa aatgtctctg 360
 atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420
 gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480
 gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctacagagtcc aattaaaaa 540
 acagaaatac caggtagtgt tctacaacca gatgcatcac cttctaaaac tggtagatta 600
 10 acctcaatac cagttacaat tccagaaaaa acctcacagt ctcaagtaat aggcactgag 660
 ggtggaaaaa atgcaagcac ttacagcaacc agccggtctt attccagtat tattttgccg 720
 gtggttattg ctttgattgt aataacactt tcagtatttg ttctggtggg tttgtaccga 780
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840
 aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtctgg tgagcactct 900
 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcaataat 960
 15 tgcgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020
 aatcccagact tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgatg 1080
 tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tcctgttctc 1140
 tcacatttaa aaattccatt actccattta caggagcgtt cctaggaaaa ggaattttag 1200
 20 gaggagaatt tgtgagcagt gaactctgaca gccaggaggg tgggctcgct gataggcatg 1260
 actttcctta atgttttaaag ttttcggggc caagaatttt tatccatgaa gactttccta 1320
 cttttctcgg tgttcttata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380
 gcagggaaaa gttgcacgtg tattattaaa tattaggtag aaatcatacc atgctacttt 1440
 gtacatataa gtattttatt cctgctttcg tgttactttt aataaataac tactgtactc 1500
 25 aatactctaa aaatactata acatgactgt gaaaatggca aaaaaa
 <210> 31
 <211> 750
 <212> DNA
 <213> Human
 30 <400> 31
 cacttgggca cccccatttt ctaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60
 aagggaagtg cctctgatgg cccaaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120
 35 atagcaaatg gatccttttt ggcctccttt ggagcatgcc ttccctatct tatccttggc 180
 cccactaaag cagaacgtta cggatatttc tgtttttgcc attggatgcc tatctggcca 240
 aacagccttt ccctaattgg aaaaatgcagt cctgtttaaa acctttgatt tacgactact 300
 tgtataatgt tgctcattac aattttgaca ttttttacct agtgaagacc ccaaacatat 360
 40 cagtgaatac tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420
 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaattcac tgagttatac 480
 ttttaaatgc ttccctcagca cactatttcc catgcattaa atatgataaa ataactctatc 540
 actgcccacg ggtcttgtaa aaaggaagtc tgaatacaga gccacaaca ctaaaattgt 600
 tttctagct acaaaagtata gcatcatcaa cacagacacg atttggaact cctgacaggt 660
 45 ggattggaaa acggtgttta aagagaagag aacattttta cataaatgtc attaagaatc 720
 ccaaaggcct tatttgtcac caccgtcccg
 <210> 32
 <211> 1620
 <212> DNA
 50 <213> Human
 <400> 32
 gcaattcccc cctcccacta aacgactccc agtaattatg tttacaaccc attggatgca 60
 55 gtgcagccat tcataagaac cttggtgccc cagaaaaatc tgtccttttt ggtaccaaac 120
 ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180
 atctgtgcaa actctgatga tacctgcctt atgtggatc ttttccacac tgctttcatt 240
 ttttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300
 atgttctggg ttttttcctt ctttttagaa ccccgctcc atttaaaaa ttaaaaaaaa 360
 60 aaaaaaaact ttttaacattt aaaaaataaa aattaacaaa atttacttta ttccaggaca 420
 cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgttt 480
 tccataattt tcacacaata acagtccctt tctatccagc ttgccttcca tttatctcta 540
 ggggttagctt ttcaggcaac atccttggtc attgccaga aagtacctga gctatcagtg 600
 attggaatgg cacaggaaac cgaatccatc ggggtgccctc cccttggttt tcaagtatct 660
 65 tggagttgtg cacaaaaaatt aggtcatgcc ttcagtgtct tgttctttaa acctaccctt 720
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaaatgt 780

gtgttcctcc taggttgaa gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840
 gtcagtgtg tcttttcacc tcgatttgtg aattaataga attgggggga gaggaatga 900
 tgatgtcaat taagtttcag gtttggcatg atcatcattc tcgatgatat tctcactttg 960
 5 tcgcaaatct gcccttatcg taagaacaag tttcagaatt ttccctccac tatacgactc 1020
 cagtattatg tttacaatcc attggatgag tgcagcatta taagaccttg gtgccagaa 1080
 aaatctgtcc tttttggtac caaacctgag gtcttttgga agataatgta gaaaaccact 1140
 acctattgaa ggcctgtttt ggctaactct tgcaaacctc gatgatacct gcttatgttg 1200
 attcttttcc acactgcttt catttttaag tataaagact tagaaaaacta gaataatgct 1260
 10 tttacaaata attaaaagta tgtgatgttc tgggtttttt ccttcttttt agaaccctgt 1320
 atttaaacaa gccttctttt taagtcttgt ttgaaattta agtctcagat cttctggata 1380
 ccaaatcaaa aacccaacgc gtaaacacagg gcagtatttg tgttcctaata tttaaaaagc 1440
 tttatgtata ctctataaat atagatgcat aaacaacact tccccttgag tagcacatca 1500
 acatacagca ttgtacatta caatgaaat gtgtaactta aggttattat atatataaat 1560
 15 acatatatac ctttgaacc tttatactgt aaataaaaaa gttgctttag tcaaaaaaaa 1620
 <210> 33
 <211> 2968
 <212> DNA
 <213> Human
 20 <400> 33
 gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60
 25 gaggaggaag aagaggaaga agaagatgaa gaaagtgaag aggaggagga agaggaggga 120
 gaaagtgaag gcagtgaagg tgatgaggaa gatgaaaagg tgtcagatga gaaggattca 180
 gggaagacat tagataaaaa gccaaagtaa gaaatgagct cagattctga atatgactct 240
 gatgatgatc ggactaaaga agaaagggct tatgacaaag caaaacggag gattgagaaa 300
 cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360
 30 gtacttgggc atgtggacac agggaagaca aaaattctag ataagctccg tcacacacat 420
 gtacaagatg gtgaagcagg tggatcaca caacaaattg gggccacca tgttcctctt 480
 gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540
 ccaggaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600
 ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg tttggagccc 660
 35 cagacaattg agtctatcaa ccttctcaaa tctaaaaaat gtcccttcat tgttgactc 720
 aataagattg ataggttata tgattggaaa aagagtcctg actctgatgt ggctgctact 780
 ttaaagaagc agaaaaagaa tacaaaagat gaatttgagg agcgagcaaa ggctattatt 840
 gtagaatttg cacagcaggg tttgaatgct gctttgtttt atgagaataa agatccccgc 900
 acttttgtgt ctttggtagc tacctctgca catactggtg atggcatggg aagtctgatc 960
 40 taccttcttg tagagttaac tcagaccatg ttgagcaaga gacttgcaac ctgtgaagag 1020
 ctgagagcac aggtgatgga ggttaaagct ctcccgggga tgggcaccac tatagatgtc 1080
 atcttgatca atgggcgttt gaaggaagga gatacaatca ttgttcctgg agtagaagg 1140
 cccattgtaa ctgagattcg aggcctcctg ttacctcctc ctatgaagga attacgagt 1200
 aagaaccagt atgaaaagca taaagaagta gaagcagctc agggggtaaa gattcttgga 1260
 45 aaagacctgg agaaaacatt ggctggttta cccctccttg tggcttataa agaagatgaa 1320
 atccctgttc ttaaagatga attgatccat gatttaaaagc agacactaaa tgctatcaaa 1380
 ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttctttgga agctctactg 1440
 gaatttctga aaacatcaga agtgccttat gcaggaatta acattggccc agtgataaa 1500
 aaagatgta tgaaggcttc agtcatgttg gaacatgacc ctgagtatgc agtaattttg 1560
 50 gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatagttt aggagttaga 1620
 attttttagt cagaaattat ttatcattta ttgatgcct ttacaaaata tagacaagac 1680
 tacaagaaac agaaacaaga agaatttaag cacatagcag tatttccctg caagataaaa 1740
 atccctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacgggtgaa 1800
 gcaggtcagg tgaacacagg gacacccatg tgtgtcccaa gcaaaaattt tgttgacatc 1860
 55 ggaatagtaa caagtattga aataaacat aaacaagtgg atgttgcaaa aaaaggacaa 1920
 gaagtttgtg taaaaataga acctatccct ggtgatgcac ccaaaatgtt tggaagacat 1980
 gactgggttca gagatgaaat gcagaagagt gactggcagc ttattgtgga gctgaagaaa 2100
 gtatttgaat tcatctaatt ttttcacatg gagcaggaac tggagtaaat gcaatactgt 2160
 gttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttt gacactgatg 2220
 60 gacttaagta tgggaaggaag aaaaataggt gtataaaatg ttttccatga gaaaccaaga 2280
 aacttacact ggtttgacag tggctcagta catgtcccca cagttccaat gtgcctgttc 2340
 actcacctct cccctcccca acccttctct acttggtctg tgttttaaaag tttgcccttc 2400
 cccaaatttg gatttttatt acagatctaa agctctttcg attttatact gattaaatca 2460
 65 gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattcttgg gacttttttg 2520
 acgtaagaaa tacttcttta tttatgcata ttcttccac agtgattttt ccagcattct 2580
 tctgccatag gcctttaggg cttttataaa atagaaaatt aggcattctg atatttcttt 2640

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacgagt ccattgtaat catcacaatt ctaaaacaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc aactacctt 2880
 5 ggtatgccag cacctgggta acagtaggag attttatata ttaatctgat ctgtttaatc 2940
 tgatcgggtt agtagagatt ttatacat

<210> 34
 <211> 6011
 10 <212> DNA
 <213> Human
 <400> 34

15

acggggcgcc ggacgaccgg cacatcttat cctccacgcc ccactcgcac tcggagcggg 60
 accgccccgg actccccctc gggecgccca ctcgaggagt gaggagagag gccgcccggc 120
 20 cggcttgagc cgagcgcagc accccccgcg ccccgcgcca gaagtttggg tgaaccgggc 180
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggagggag 240
 ggaactcccc cggcccaagg ctctgtgggt cggggtcgcg cggccgcaga aggggcgggg 300
 tcgccccgcg aggggagggc cccccgggga cccgagaggg gggtagggac cgcgggctgc 360
 25 tgggtcggcg gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tccgggcccg 420
 gctgcgagga ggaggcggcg gcggcgagcagg aggatgtact tgggtggcggg ggacaggggg 480
 ttggccgggt gcgggcacct cctgggtctcg ctgctggggc tgctgtctgt gccggcgcg 540
 tccggcaccg gggcgctggt ctgctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
 aaccgcccgg ggagcatcgt gcaggggcgtc tgccgctgct gctacacgtg cgcagccag 660
 30 gggaacgaga gctgcggcgg caaccttcggg atttacggaa cctgcgaccg ggggctgctg 720
 tgtgtcatcc gcccccgct caatggcgac tccctcacag agtacgaagc gggcgtttgc 780
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840
 attgtcggt gcaatataat caatgggaaa ttggaatgta acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcccttcag ctttaagag aattgaagaa 960
 35 gagaagccag attgtccaa ggcccgctgt gaagtccagt tctctccag ttgtcctgaa 1020
 gattctgttc tgatcgaggg ttatgtcct cctggggagt gctgtccctt acccagccgc 1080
 tgcgtgtgca accccgagc ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaacca 1200
 gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 40 ccggacagct atgaaactca agtcagacta actgcagatg gttgtgttac tttgccaaca 1320
 agatgcgagt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctctgtggcg tgggacacct ggaaagtgtc gtgatgtctt tgaatgtgtt 1440
 aatgatacaa acccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgtatg caagggggcg ttgccatctg cttcaccgcc 1560
 45 cagtgtggtg agataaactg cgagaggtag tacgtgcccc aaggagagtg ctgcccagtg 1620
 tgtgaagatc cagtgtatcc ttttaataat cccgctgggt gctatgccaa tggcctgatc 1680
 cttgcccacg gagaccgggt gcgggaagac gactgcacat tctgccagtg cgtcaacggg 1740
 gaacgccact gcgttgcgac cgtctcgga gaggacctga caaacctgt gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttagatc acctgcatgt 1860
 50 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggtt caaacgcgat 1920
 cacaatggt gtcggacctg tcagtgcata aacacccagg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggt ttccttactg atgcccacaa ctgtgagatc 2040
 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 55 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtacagg ctgtcttatc 2220
 tgcaagtgca gagaggcctc tgcttcagct gggccaccca tctgtcggg cacttgtctc 2280
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgctgtggc 2400
 aacccccacca ttcacctggt acagtgtgtc ccatcatgtg cagatgactt tgtggtgcag 2460
 60 aagccagagc tcagtactcc ctccatttgc cagcggcctg gaggagaata ctttgtggaa 2520
 ggagaaacgt ggaacattga ctccgttact cagtgcacct gccacagcgg acgggtgctg 2580
 tgtgagacag aggtgtgcc accgtgtctc tgccagaacc cctcacgcac ccaggattcc 2640
 tgctgcccac aggttacaga tcaacctttt cggccttcct tgtcccga taacagcgta 2700
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 65 gacgtttgta ccagctgcat ctgcattgat agcgttaatta gctgtttctc tgagtcctgc 2820
 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgtgtcc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagt ggaaggccta tgccgacgag 2940

gagcgggtggg accttgacag ctgcacccac tgctactgcc tgcagggcca gacctctgc 3000
 tgcaccgtca gctgcccccc tctgccctgt gttgagccca tcaacgtgga aggaagtgc 3060
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
 5 aaccatcgag gagagggtga cctggagggt cccctgtggc ccacgcctag tgaaaatgat 3180
 atcgccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240
 cacccaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300
 tgctctctta ttataatagc attcctattc atcaatcaga agaaacagtg gataccactg 3360
 ctttgctggt atcgaaacac aactaagcct tcttccttaa ataatcagct agtatctgtg 3420
 gactgcaaga aaggaaccag agtccagggt gacagttccc agagaatgct aagaattgca 3480
 10 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600
 gacgactaaa tctgctctaa aaagtaaaact agaatttgtg cacttgctta gtggattgta 3660
 ttggattgtg acttgatgta cagcgtctaa accttactgg gatgggctct gtctacagca 3720
 atgtgcagaa caagcattcc cacttttctt caagataact gaccaagtgt tttcttagaa 3780
 15 ccaaagtttt taaagttgct aagatatatt tgcctgtaag atagctgtag agatatttgg 3840
 ggtggggaca gtgagtttgg atggggaaag ggggtggagg gtggtgttgg gaagaaaaat 3900
 tggtcagctt ggctcgggga gaaacctggt aacataaaaag cagttcagtg gccagagggt 3960
 tatttttttc ctattgctct gaagactgca ctggttgtg caaagctcag gcctgaatga 4020
 gcaggaaaca aaaaaggcct tgcgaccag ctgccataac caccttagaa ctaccagacg 4080
 20 agcacatcag aacctttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140
 cagtcacaac tgcagtaggc agtgaggaaag ccagagaaat gcgtagcgg catttctcta 4200
 aagcgggtta ttaaggatat atacagttac acttttctgt gcttttattt tcttccaagc 4260
 caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380
 25 gaacaccagg catttccagg ggctatatat cactgtttgt tgttgccttg ttctgttata 4440
 ttgttggttg ttcatagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500
 gactgttttg ggattctttt tctttattat atactgattc taaaaaatag aaactacttc 4560
 attttaattg tatattattc aagcaccttt gttgaagctc aaaaaaatg atgcctcttt 4620
 aaacttttagc aattatagga gtattttatg aactatctta tgcttcaaaa aacaaaagta 4680
 30 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740
 tgttttcttg ttgaatgtat ttttatgaga ttttaaccag aacaaaaggca gataaacagg 4800
 cattccatag cagtgccttt gatcacttac aaattttttg aataacacaa aatctcattc 4860
 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920
 35 gtgtgtgcgc gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980
 attcctttat taaaatcttc ctcatgttga tttgctttca gttggttttc aatttgctca 5040
 ctggccagag acattgatgg cagttccttat ctgcatcact aatcagctcc tggatttttt 5100
 ttttttttt tcaaacaaatg gtttgaaaca actactggaa tattgtccac aataagctgg 5160
 aagtttgttg tagtatgcct caaatataac tgactgtata ctatagtggg aacttttcaa 5220
 acagccctta gcacttttat actaatatac ccatttgtgc attgagtttt cttttaaaaa 5280
 40 tgcttgttgt gaaagacaca gatacccagt atgcttaacg tgaaaagaaa atgtgttctg 5340
 ttttgtaaag gaactttcaa gtattgttgt aaatacttgg acagaggttg ctgaacttta 5400
 aaaaaaatta atttattatt ataataacac aattttattt tctgaagatt aaccttttt 5460
 ttgtcttaga atatacaaaa gaaaaagaaa aaggtgttct agctgtttgc atcaaaggaa 5520
 45 aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaataaat ttgttaataa 5580
 tacattacaa aaatagattg acatcagcct gattagatata aattttgttg gtaattaatc 5640
 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgcct tttgtttttt 5700
 caatcatggc catattatga aaatactaac aggatataag acaagggtga aattttttta 5760
 ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttacttttgt 5820
 tcctgttgtg ctcttgtaaa agaaaaatat aatttctgta agaataaaat agatatatgg 5880
 50 cacttgagtg gcatcatagt tctacagttt gtttttgttt tcttcaaaaa agctgtaaga 5940
 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000
 aaaaaaaaaa a

55 <210> 34a
 <211> 1036
 <212> DNA
 <213> Human

60 <400> 34a

mylvagdrgl agcghllvsl lgllllpars gtralvclpc deskceprn rpgsivqgvc 60
 gccytcasgg nescggtfgi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120
 65 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180
 vqfsprcped svliegyapp gecclplsrc vcnpagclrk vcqpgnlnil vskasgkpge 240

5 ccdlyeckpv fgvdertvec ptvqgtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300
pvcevgtstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmdfr mdncrfrcrcq 360
ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceept iitvdppacg elsnctltlk 480
10 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfgf ltdaqnceic ecrprpkkr 540
piicdkycpl gllknkhgdc icrckkcpel scskicplgf qgdshgcllc kreasasag 600
ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpggqccp 660
scaddfvvqk pelstpsich apggeyfveg etwnidsctq ctchsgrvlc etevcppllc 720
qnpstqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkp vctscicids 780
10 viscfsecp svscerpvlr kgqccpycik dtipkvvch fsgkayadee rwdldscthc 840
yclggqtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekt nhrgevdlevp 900
lwptsendi vhlprdmghl qvdyrdnrh psedssldsi asvvvpiliic lsiiiaflfi 960
nqkkqwipll cwyrtptkps slnnqlvsvd ckkgrtvqv dssqrmrliae pdarfsgfys 1020
15 mqkqnhlqad nfyqtv

<210> 35
<211> 716
<212> DNA
20 <213> Human

<400> 35

25 gcagtagctg gagtgtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
acccggggct cctggggccg tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
30 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
ttgagggaat ctcctgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360
aaggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
gtcagtgtgg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480
ccattctggt cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
tctggttagt gtcgtaacct ctgtgtgcct ccggttacc catctgtcca gtgagctcag 600
35 ccccatcca cctaacaggg tggccacagg gattactgag ggttaagacc ttagaactgg 660
gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36
<211> 395
40 <212> DNA
<213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcc tttactacat 120
tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaaat 180
atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
gcccagtaaa accaaagtca gggttaacaa tgtcatttta caaaatgtta aaaccctaata 300
50 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
agaagcaagg aaagcattct taattctacc atcct

<210> 37
<211> 134
55 <212> DNA
<213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
aaccataaa gctgcctggc tttcagcaac aggcctatca acaccatggt gacttccat 120
aaggacacc ggt

<210> 38
65 <211> 644
<212> DNA

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
 cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
 gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatatttg tggggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
 gcttgggtgaa gttacgaaac ttgtccaaaa tgtaaaaggc acagccaaga 300
 10 ttcagagcca ggctgtaaaa attaaaaatga acaaattacg gcaaagtgtt aggagaaaga 360
 aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
 ttcgcaccgg aaaatgtagc ttcccgttta agtaccttgg ccatgtagaa gttgatgaat 480
 caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540
 tcaaaggctt ctttggaaaa actggaaaga aagcagttaa agcagtttct gtgggtctaa 600
 15 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

ctttttgttt ggggttttcca atgtagatgt ctcaagtgaat tgtgcagata tactttgttc 60
 25 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
 gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
 tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
 acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
 agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
 30 tggctcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
 ttttttgttt tttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaatcagct 480
 aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
 taagaaatcac tactacattt aacattataa agtagagttc tggacataac tgaattatag 600
 atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

35

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

acaattttta aataactagc aattaatcac agcatatcag gaaaaagtag acagtgaagt 60
 ctggttagtt tttgtaggct cattatggtt agggctggtt agatgtatat aagaacctac 120
 45 ctatcatgct gtatgtatca ctcatcccat tttcatgttc catgcatact cgggcatcat 180
 gctaataatgt atccttttta gcaactctca ggaacaaaaa gggcctttta tttttataaa 240
 ggtaaaaaaa attcccaaaa tttttgcac tgaatgtacc aaagggtgaag ggacattaca 300
 atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
 acttccctca cagtgccttg tctaccacta caaggactgt gcatctaagt aataattttt 420
 50 taagattcac tatatgtgat agtatgatat gcatttattt aaaatgcatt agactctctt 480
 ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
 gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
 tgaagagatc agtagtaaga attccatttt cctcatcag tgaagacacc acaaattgaa 660
 actcagaact atatttctaa gcctgcattt tcaatgatgc ataattttct tagtaatat 720
 55 aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
 ttaattttat gagaaggat tcttcatatt aattgctttt gggattactc cacatctttg 840
 tttatttctt gactaatcag attttcaata gagtgaagt aaattggggg tcataaaagc 900
 attggattga catatggttt gccagcctat ggggtttacag gcattgccc aacatttctt 960
 tgagatctat atttataagc agcatggaa ttctatttat gggatgttg caatcttaca 1020
 60 ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
 gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
 ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200
 tggaaataag aaagggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
 65 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata ttttaattt 1320
 tgaaaaaa

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

10 aacagagact ggcacaggac ctcttcattg caggaagatg gtagttagg caggtaacat 60
 tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120
 taacccccgg ctatcagtcc ggatgggtgc caccctcct gctgtaggat ggaagcagcc 180
 atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
 tggttctacc tcttctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
 tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcatg 360
 15 aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
 ggaggaggga ggagctggta gggagatgct ggctttacct aaggctctga aacaaggagg 480
 gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540
 tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
 gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
 cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
 20 tgaggcttgt gatacctggt ttgaagggtt gctgagaaaa ttaagataa gggatccaa 780
 aatagtctac ggccatacca ccctgaacgt gcctaattc gtaagctaag cagggtcagg 840
 cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttag 900
 actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960
 25 tgaagtagcg atttggtgtg aaaaaaa

25

<210> 42
 <211> 956
 <212> DNA
 <213> Human

30

<400> 42

35 cggacgggtg ggcggacgcg tgggtgcagg agcagggcgg ctgccgactg cccaaccaa 60
 ggaaggagcc cctgagtccg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
 ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
 tcaggggatg tttacctggt gctcgggaag ggagggggaa gggccgggga gggggcacgg 240
 caggcgtgtg gcagccacac gcaggcggcc agggcggcca gggacccaaa gcaggatgac 300
 cagcacctc cagccactg cctccccga atgcatttgg aaccaaaagtc taaactgagc 360
 40 tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agcgtcttgg acagatggac 420
 gcaggccctg tccagcccc agtgcgctcg ttccgggtccc cacagactgc ccagccaac 480
 gagattgctg gaaaccaagt caggccaggt gggcggacaa aaggggccagg tgcggcctgg 540
 ggggaacgga tgctccgagg actggactgt tttttcaca catcggttgc gcagcggtgg 600
 gaaggaaaagg cagatgtaaa tgatgtgttg gtttacaggg tatattttt atacctcaa 660
 tgaattaatt cagatgtttt acgcaaggaa ggacttacc agtattactg ctgctgtgct 720
 45 ttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcgggtg accccatcac 780
 tcgcaggacc aagggggcgg ggactgctgg ctcacgcccc gctgtgtcct ccctccctc 840
 ccttcccttg gcagaatgaa ttcgatgctg attctgtggc cgccatctgc gcagggtgg 900
 ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

50

<210> 43
 <211> 536
 <212> DNA
 <213> Human

55

<400> 43

60 aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
 cccctagttt cttaaagtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
 agtgtagtct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
 ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagttaga gagcatatga 240
 tctaaataaa gacatttgaa gggtagtttt gaattctaaa agtaggtaat agccaaatag 300
 cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
 attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420
 ctggaaaaag tgggttatgc cacttttaaa accctttctg gtaaatatta tggtagctaa 480
 65 aggggtggtt ccccgccacc tggacctgga caggtagggg tccgtgggta accagt

<210> 44
<211> 1630
<212> DNA
<213> Human

5

<400> 44

10 ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
atccccctctg gaggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgatttccc ttagggccag gacttgggcc tccagctcat ctgttccttc tggggccatt 360
catggcaggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
15 gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
attaggaagt cgggggtggg tgggtgggtgg gggctagtgg gggttgaatt taggggcca 660
20 tgagcttggg tacgtgagca ggggtgtaag ttagggtctg cctgtatttc tgggtcccct 720
ggaaatgtcc ccttcttcag tgtcagacct cagtcccagt gtccatatcg tgcccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggg 840
gcccagtgac ctgggggagc ctgggtgcag gccctcactg gttccctaaa ccttgggtggc 900
tgtgattcag gtcccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
25 gagttggctg cttagagcctt cttagaggttc agaattattag cttcaggatc agctgggggt 1020
atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa ccccccaagt 1140
aggctggagg gagttaaggt cagtatggaa gatagggttg ggacaggggtg ctttgggaatg 1200
aaagagtgc cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260
30 gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
ctgggtccct tgtagcacag gagactgggg ctaagggccc ctcccaggga agggacacca 1380
tcaggcctct ggctgaggca gtacataga ggatccattt ctacctgcat ttcccagagg 1440
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
35 cctcttgctt cttgtagaat gcagctctgg ccctcaataa atgcttctct cattcatctg 1620
caaaaaaaaa

<210> 45
<211> 169
<212> DNA
<213> Human

40

<400> 45

45 tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac atagggtctga 60
taaaactggg ttatgatctt cagtctgatt ccagtgtctc ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttgggaaga cttagtgtga

<210> 46
<211> 769
<212> DNA
<213> Human

50

<400> 46

55 tgcaggatcat atttactatc ggcaataaaaa ggaagcaaag cagtattaag cagcgggtgga 60
atttgcgct ttcacttttt ataaagtgtc acataaaaatg tcatatttcc aaatttaaaa 120
acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180
aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240
aaggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
60 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
ggccagctcc ttccctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgaggtt 600
65 ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
 gtgaaaatta gtgactggtt aagggtgtgcc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagtcac acaagggtgg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 15 gccttaactta gctcctggca gaggtgagtg ggggacctac gaggttcaaa atcaaatggc 360
 atttgccag cctggcctta ctaacaggtt ccagagtgct ctctgttggc tgagctctcc 420
 tgggctcact ccatcttcat gaagagtcca aatgattcat tttcctaccc acaacttttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga ctttaagtcct ctctccctcc 540
 actagtggg gccactgcac tgaggggggt ccaccaatt ctctctagag aagagacact 600
 20 ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagtg 660
 ggtgccagg aatgttttaa atctatcagg cactactata agctggtggt ttcttcctac 720
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaaccac 780
 tgaactcttg tgttgacagg tacaaggag aagagatggg gactgtgaag aggggagggc 840
 ttccctcctc ttccctcaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900
 25 gcaatagatg gggcttccta ccatctgttg gttattgctg gggttagcca ggagcagtg 960
 ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc ttgggggtct 1020
 ccagaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tcctacctgc ttggtacct agtccctcaa taagattcag aggaagaagc 1140
 ttatgaaact gaaaaatcaaa tcaaggtatt gggaagaata atttccctc gattccacag 1200
 30 gaggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260
 acaaatcatc aggggttgcc tgcttgccag tcacatgctt ccctggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcat 1440
 gcagtgggc tgacctgaca aagccccag tttcctgtgg cagggttctg gagaggatgc 1500
 35 attcaagctt ctgcagccta ggggacagg ctgcttgttc agttattact gcctcggagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 cttcggcagt attctcggt gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
 40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtgg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
 ctctatctga ggagcccca ctggttccag aagcaactta ccaagggtga tttaaagaca 2040
 tgaattttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100
 45 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
 gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaaag 2220
 gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggtc 2280
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cagctcacca 2400
 50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
 ggggtgtcc

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
 ttcataatata tatatacata catatataaa ggaacaatt tgcaaatata cacacctgac 120
 aaaaccatata atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 ctaggcaggc cgtttttcca tccctaagta ccattctctc atttggggcc ttctagggtt 240
 65 gggggcctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
 tgaaggacag ttagacacct atctttgtct gctccccgct gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga cacgggggat tgaggcta at tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttctttt ttttctcga 480
 gacggagtct cgctgtgttg cccaggctgg agtgacgtgg cacggctctc gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720
 aagtgtctgg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttcctggcct ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caaactgca gctcctctg gatgctgctg ggggtgcttc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtgaagc cagcctttgg ggaggaagc cagctcagag 1020
 aggtaccaca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
 ggtgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggctctgc 1200
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgaggggagc agggagcttc tctctagtcc ctttggaggc tttggctgag agaagagtga 1320
 gcaggagctt gggaaatggc caggcaggga agggagctga agtgattcgg ggctaattgc 1380
 tcagatcgat gtatttctct ccctggctc cggagccct cttgtcaccg ctgctgccct 1440
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 20 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtgggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagtggga 60
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaaaacaaca aaaagcagaa acgctgaagg ggtcgggtta cgggaaaacc 180
 gcctgtcaga acacttggtc actcctaccc cagatcagtg gacctgggaa tgagggttgg 240
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300
 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tgggggtggag 360
 35 ggagggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcag ggcaagcatg 420
 tgcgtgcctg tgtgtgtgcg tgcccctccc ctgcagccgt cgggtggtatc tccctccagc 480
 cccttcgcca cttcttgagc attgtctgtc cactgagac tgcccagaga cagcagagct 540
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgcctg atctcatgac 600
 cagggtgctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
 40 gtcccgtgta cctgcccccg tggcgtctca cgggtgatgc tgctcctgac attggtgttc 720
 actgtagcaa actacattct ggatgggaat ttcatgtac atgtgtggca tgtggaaaat 780
 ttcaataaaa atggacttga tttagaaaag caaaaagctg tgtggctcct ccagcacgga 840
 tactttgacc tcttgacctac aacccttccc ttgggtccga ggctggtagc tttgttact 900
 45 tcagatgggt gggggcgggt g

<210> 50

<211> 338

<212> DNA

<213> Human

50

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttcag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc accctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac cataactcaat gatccttcgt 240
 cactgtgtgc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgetaca 300
 gtaagaaact ttctttcttg aattcttgggt tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

	ctagcaagca	ggtaaaccgag	ctttgtacaa	acacacacag	accaacacat	ccgggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tggtggctct	ctgtgccact	120
	cctggaaaat	aatgaattgg	gtaaggaaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
5	aaacttgtca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgctcgga	gacgctcctg	acaagtcggg	360
	aatttctcta	tttctccact	ggtgcaaaga	gcggatttct	ccctgcttct	cttctgtcac	420
	ccccgctcct	ctcccccagg	aggctccttg	atztatggta	gctttggact	tgcttccccg	480
	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	ggtgaaggga	agactccagg	540
10	ccatcacaga	taaaagaaaa	atacaggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gagggagaaa	tggtctctag	660
	atggaatcag	cagcggaaaa	gaacaggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
	aaaaagctga	actgcaaadc	tcaacgaagg	aagaggccat	tttaagaaa	ctaaagtcaa	840
15	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
	aagagtcaat	tgaggacatc	tatgctaata	tccctgacct	tccaaagtcc	tacatacctt	960
	ctaggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaaattaaa	gttgaaaaag	acttgaagac	tggagaaaag	acagtctctg	1080
	cttccaatac	ctctggccat	cagatgactt	taaaaggtag	aggagtataa	gtttaagatg	1140
20	atgggcaaaa	gtccagtgtg	ttcagtaaa	tgctaatac	aagttggagg	t	
	<210>	52					
	<211>	1200					
	<212>	DNA					
25	<213>	Human					
	<400>	52					
	aacagggact	ctcactctat	caaccccagg	ctggagtcgg	gtgcgcccac	cctggctccc	60
30	tgcaacctec	gcctcccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	tttttgtaga	gacagggttt	180
	cgccttctgt	ccaggccggc	atcatatact	ttaaatcatg	cccagatgac	tttaatacct	240
	aatacaatat	atcaggttgg	tttaaaaaata	attgcttttt	tattattttt	gcatttttgc	300
	accaacctta	atgctatgta	aatagttgtt	atactgttgc	tttaacaacag	tatgacaatt	360
35	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtg	tttcaattcc	tccttggttg	aatccatgga	tgcaaaaccc	acagatatga	480
	agggtctggc	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagt	aaagtattgg	tacagtggaa	agagtgttgg	aaaacataaa	catttggacc	600
	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggctc	660
40	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagtct	cagttgcctc	720
	acctgtaaaa	tgaagaact	ggatactctc	taaggctcact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaat	840
	gattattaaa	gtgggaaaaa	gccaaattgct	tctcttagaa	agctcaacta	aatttgagaa	900
	gaataatctt	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctattttatt	960
45	agagatgggg	tctcactctg	tcacccagac	tggagtacag	tggcacaatc	atagctcact	1020
	gctgcctcaa	attcatgggc	tcaagtgatc	ctcctgcctc	tgctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgattt	gacctattta	tttattgtga	1140
	tttatatctt	tttttttttt	tctttttttt	ttttttacaa	aatcagaaat	acttattttg	1200
50	<210>	53					
	<211>	989					
	<212>	DNA					
	<213>	Human					
55	<400>	53					
	aagccaccac	tcaaaacttc	ctatacattt	tcacagcaga	gacaagtga	catttatttt	60
	tatgcctttc	ttcctatgtg	tatttcaagt	ctttttcaaa	acaaggcccc	aggactctcc	120
60	gattcaatta	gtccttgggc	tggtcgactg	tgaggagtc	cagggagcct	ctacaaatgc	180
	agagtgaact	tttaccaca	taaaccctag	atacatgcaa	aaagcaggac	ccttctctca	240
	ggaatgtgcc	atttcagatg	cacagcacc	atgcagaaaa	gctggaattt	tccttggaac	300
	cgagtgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccagget	gagtgcattg	cgatgatctc	ctcactgcaa	ttccacctcc	420
	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccaccatg	480
65	ccggctaatt	ttgtattttt	gtagagatgg	atctctccat	ttggtcaggc	ggtctcgaa	540
	cccaacctca	gtgatctgcc	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660
ttctctgaag tacttgataa aattttccaaa caaaacacat gtccacttca ctgataaaaa 720
atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
5 ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcccttttg aaatcagtta 840
ttaatattat tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900
tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtgc actggcgcaa 960
gcccggctca ccgcaatctc tgccaccgc

<210> 54
10 <211> 250
<212> DNA
<213> Human

<400> 54
15 catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60
gcagaggcta ctacaagaag taggggaatca agtccctcac atgggctatt aaaactaggt 120
agtgggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
aaagggcatt ctttaggaac tgcatctggg aaccacacac ttgatccaag agctagggaa 240
20 acttcagttg

<210> 55
<211> 2270
<212> DNA
25 <213> Human

<400> 55
30 gcgccccga gcagcgcccg cgcctccgc gccttctccg ccgggacctc gagcgaaga 60
ggcccgcgcg ccgcccagcc ctgcgcctccc tgcccaccgg gcacaccgcg ccgccacccc 120
gaccccgctg cgacaggcct gtccgctgca caccagcttg ttggcgtctt cgtcgccgcg 180
ctcgccccgg gctactcctg cgcgcacaa tagctcccg catcgccagg gcgctcgctt 240
tagtcgtcac ccttctccac ttgaccaggc tggcgctctc cacctgcccc gctgcctgcc 300
actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtccgg gacggctgcg 360
35 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420
accacacca ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480
gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaaacgggg 540
aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600
ttctctgtg tcccaagaa ctatctctcc ccaacttggg ctgtcccaac cctcggtcgg 660
40 tcaaagttac cgggcagtgc tgcgaggagt gggctctgta cgaggatagt atcaaggacc 720
ccatggagga ccaggacggc ctccctggca aggagctggg attcgatgcc tccgaggtgg 780
agtgtacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggtccc 840
ctgttttttg aatggagcct cgcctcctat acaacccttt acaaggccag aaatgtattg 900
ttcaaaacac ttcatggtcc cagtgtctaa agacctgtgg aactgggtatc tccacacgag 960
45 ttaccaatga caaccctgag tgccgccttg tgaaagaaac ccggatttgt gaggtgccc 1020
cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080
aatccccga accagtcagg ttacttctac ctggatgttt gagtgtgaag aaataccggc 1140
ccaagtactg cggttcctgc gtggacggcc gatgctgcac gccccagctg accaggactg 1200
tgaagatgag gttccgctgc gaagatggg agacattttc caagaacgctc atgatgatcc 1260
50 agtccctgcaa atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320
ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380
cctagacaaa caaggagaaa gagtgtcaga atcagaatca tggagaaaat gggcggggt 1440
gggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500
ggtatttoga aactgccaag ggtgctgggt cggatggaca ctaatgcagc cagcattgga 1560
55 gaatactttg cttcatagta ttggagcaca tgttactgct tcatttttga gcttgtggag 1620
ttgatgactt tctgttttct gtttctaagt ttttgctaa gcatattttc tctaggcttt 1680
tttccctttg ggttctaca gtctgtaaaag agataataag attagtgtga cagtttaaag 1740
cttttattcg tcccttgaca aaagtaaag ggagggcatt ccatcccttc ctgaaggggg 1800
acactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
60 ggtgttttaa gactgaatgt tttatttatc aaaatgtagc ttttggggag ggaggggaaa 1920
tgtaatactg gaataatttg taaatgattt taattttata ttcagtgaag agattttatt 1980
tatggaatta accatttaat aaagaaatat ttacctaata tctgagtgtg tgccattcgg 2040
tatttttaga ggtgtccaa agtcattagg aacaacctag ctcacgtact caattattca 2100
aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160
65 ttataccttc agtagagaaa agtcttttga tataaagtaa tgtttaaaaa acatgtattg 2220
aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56
 <211> 1636
 <212> DNA
 5 <213> Human

<400> 56

10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaaggga 60
 agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccg ggcggcccccac 120
 cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180
 tggtttgctt ggtctcaagg aactgcatc gtcaaaactga tcccctggcc gttggaggag 240
 cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaagg 300
 15 cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
 agcccggtggc cttccccacc cagcaggaag ctctgggcac gccaccaccc ccaagtggcc 420
 gatgtctctt gcctggttct tgctacggga ctcaacgatg ggagatcaa gatctgggag 480
 gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
 agcttcacac ccagtggcag tttgattttg gtctccgctg cacgggataa gactcttcgc 600
 atctggggacc tgaataaaca cggtaaacag attcaagtgt tatcggggca cctgcagtgg 660
 20 gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720
 tcggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
 agcagtggtg tctcttgtga cttctcccc gactctgccc tgcttgtcac ggcttcttac 840
 gataccaatg tgattatgtg ggaccctac accggcgaaa ggctgaggtc actccaccac 900
 25 acccagggtg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
 tggggccctg aactgaaaac tcccattgca tttgtccta tgaccaatgg gctttgctgc 1080
 acatttttcc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
 tggacagctc ctagggtcct gtccctcactg aagcacttat gccggaaaagc ccttcgaagt 1200
 30 ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagtctctc 1260
 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320
 cctgtcaaag ggaagtgctg gaataatggg ccaaaccatct ggtcttgcac tgaaatagca 1380
 tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
 tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagtgtga acttatattg 1500
 aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
 35 aagatggtga aggtgaggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
 gaccctgtgc tgcgtt

<210> 57
 <211> 460
 40 <212> DNA
 <213> Human

<400> 57

45 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
 gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
 tggaaatgagc taaagcagcc gcctgggggtg ggaggccgag cccatttgta tgcagcagg 180
 ggcaggagcc cagcaaggga gcctccattc ccaggactct ggaggagact gagaccatcc 240
 50 atgcccgag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
 aactgaggct gggaagtac atagcaagt actggcagag ctgggactgg aaccaacca 360
 gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
 ccgagctcga attcgtaatc atggtcatag ctgtttcctg

<210> 58
 55 <211> 1049
 <212> DNA
 <213> Human

<400> 58

60 atctgatcaa gaatacctgc cctggctact ctgcggatgt ttctgtccac ttgttcacat 60
 tgaggaccaa gatatacttt ttacagagg cacttggtcg gtctaacaca gacacctcca 120
 tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccctccca gcctggacta 180
 cagcagcact ttcccggtgg ggtgcagtag ccgtttcgac agagcctgga gcaactctga 240
 65 gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
 ggatctacaa tttttagag ttttccattg tgagtctggg tcatactttt actgcttgat 360

5 aaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggactttgct ggagagtttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtataca aatccaccaa ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctggt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttataatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctggtt ggtgctggtt aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaaccacag taaaccaagt acaaaaaata ttcataataa 180
 gttggttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagattttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggtctccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctgggttacc tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccctgtt ttgtctcgaa gggctccaca 660
 gcccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcaattta gtagtaatag cggccgc